# BioNTech SE share price today (BioNTech SE, BNTX)

> BioNTech SE's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. BNTX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/bntx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $85.84 (−16.8% in a year)
- P/E: 243.9× (higher than 96% of the last 2.6 years)
- Revenue (Jun 2026): $106 M (−59.5% on a year ago)
- Profit (Jun 2026), incl. one-off: −$821 M (one-off item, see below)
- Operating margin: −806.6% (−641.6 points on a year ago)
- ROE: −6%, FY25
- ROIC: −29.9%, against a 11.4% cost of capital: −41.3 points
- Profit that came in as cash: 96%, last 3 years

Biggest thing to watch: the P/E is higher than 96% of its own history, so the multiple has already done part of the work. ## What is the BioNTech SE share price today? BioNTech SE's share price was $85.84 at the close on 5 November 2026. It has been falling for 6 weeks. That is 11.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $86 and $117, and at that close it sat 1% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 4 weeks running. Over the last 7.1 years the share price moved +521% while the S&P 500 moved +147%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does BioNTech SE pay? BioNTech SE pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is BioNTech SE on? BioNTech SE is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is BioNTech SE profitable? BioNTech SE posted a net loss of $821 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $1.1 B. That loss is 777.3% of the quarter's revenue. The same quarter a year earlier lost $387 M. 8 of the last 12 reported quarters were loss-making. Read this profit with care: at −$821 M it is bigger than the quarter's whole revenue of $106 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −806.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does BioNTech SE make, and is it growing? BioNTech SE reported $106 M of revenue in the Jun 2026 quarter, −59.5% on the same quarter a year earlier. Over 4 years it has grown −37.6% a year on average. The last full year, FY25, came in at $2.9 B. The last four reported quarters add to $2.6 B. FY25 revenue was $2.9 B, +4.3% on the year before. Recent pace: the last four quarters grew −24.1% on average, against −37.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −7.9%, against −0.8% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does BioNTech SE keep? BioNTech SE's operating margin was −806.6% in the Jun 2026 quarter, 641.6 percentage points lower than the same quarter a year ago. Across 5 years it has been between −46.7% and 78.2%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −641.6 percentage points on the year while gross margin changed −62.6 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is BioNTech SE's profit turning into cash? Over the last 3 years, 96% of BioNTech SE's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $456 M of operating cash against −$1.1 B of profit. After $175 M of spending on assets, $281 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does BioNTech SE's cash go? BioNTech SE does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $712 M on assets over the last 3 years. Averaged over those years that is 8.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $712 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is BioNTech SE's P/E ratio, and how does it compare with its own history? BioNTech SE's P/E is 243.9×, near the high end of its own history: higher than 96% of past readings. Its usual P/E (the middle reading) is 6.1×, over 2.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the BioNTech SE business getting better or worse? BioNTech SE's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does BioNTech SE earn on its capital? BioNTech SE earned a ROE of −6% in FY25. Its return on capital used (ROIC) is 41.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −39.6% net margin and 0.13× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −39.6% net margin × 0.13× asset turnover × 1.14× leverage (assets divided by equity) ≈ −5.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −29.9% − 11.4% = −41.3 percentage points. The 11.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −29.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −26.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does BioNTech SE have too much debt? BioNTech SE has total debt of $316 M against shareholder equity of $17.8 B as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.01 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the BioNTech SE shareholding pattern? We have no ownership or short-position figures for BioNTech SE, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 2.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is BioNTech SE from balance-sheet trouble? For BioNTech SE, the Z-score is 7.02. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 7.02 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does BioNTech SE rank in its industry? 33.1 out of 100, rank 24 of 30 in Biotechnology, with 64% of the evidence available. BioNTech SE scores 33.1 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 24. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 9.4 + 7.9 + 11.3 + 4.5 = 33.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is BioNTech SE compared with? BioNTech SE ranks 24 of 30 Biotechnology companies on the 4-Factor Sector Score, with 33.1 out of 100. 1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) EXEL · breaking out · Most evidence points up · 81% evidence 76.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidence Valuation 14.6/20 · P/E 15.9× · PEG 0.3 · 65% evidence Relative strength 17.9/20 · Lead over its industry 9.7% · Lead over S&P 500 35.4% · 1 year 68.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 22.7 + 20.9 + 14.6 + 17.9 = 76.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Halozyme Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/halo) HALO · leader · Most evidence points up · 81% evidence 72.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.7/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidence Capital efficiency 20.9/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidence Valuation 14.6/20 · P/E 22.4× · PEG 0.25 · 65% evidence Relative strength 18.8/20 · Lead over its industry 21.7% · Lead over S&P 500 48.8% · 1 year 80.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.7 + 20.9 + 14.6 + 18.8 = 72 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) INCY · turning · Most evidence points up · 71% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidence Capital efficiency 20.5/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidence Valuation 10.9/20 · P/E 14× · PEG n/a · 15% evidence Relative strength 7.2/20 · Lead over its industry -12.7% · Lead over S&P 500 8.2% · 1 year 11.4% · 100% evidence · 5 of 12 weeks ahead Exact sum: 27.1 + 20.5 + 10.9 + 7.2 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) GMAB · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.0/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidence Capital efficiency 15.6/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidence Valuation 15.1/20 · P/E 21.4× · PEG 0.21 · 65% evidence Relative strength 19.5/20 · Lead over its industry 33.6% · Lead over S&P 500 65.2% · 1 year 83.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11 + 15.6 + 15.1 + 19.5 = 61.2 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak. 5. [argenx SE](https://www.sectoralpha.in/us/stocks/argx) ARGX · turning · Evidence leans up · 85% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidence Capital efficiency 17.1/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidence Valuation 10.4/20 · P/E 32× · PEG 1.39 · 65% evidence Relative strength 8.4/20 · Lead over its industry -17.4% · Lead over S&P 500 2.7% · 1 year 4.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 24.9 + 17.1 + 10.4 + 8.4 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) ONC · leader · Evidence leans up · 64% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 34.3% · Profit n/a · Operating margin change 12.4 points · 62% evidence Capital efficiency 13.3/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidence Valuation 9.1/20 · P/E 48.3× · PEG n/a · 15% evidence Relative strength 12.2/20 · Lead over its industry -6.3% · Lead over S&P 500 16.5% · 1 year 21.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 13.3 + 9.1 + 12.2 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) KYMR · turning · Evidence leans up · 61% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit n/a · Operating margin change 620.5 points · 62% evidence Capital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 16.9/20 · Lead over its industry 11% · Lead over S&P 500 36.2% · 1 year 118.4% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.9 + 6.8 + 10 + 16.9 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) SYRE · quiet · Too little evidence to rank firmly · 56% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue n/a · Profit n/a · Operating margin change 999.3 points · 52% evidence Capital efficiency 8.6/25 · ROCE -24.5% · Operating margin n/a · 61% evidence Valuation 11.0/20 · P/E -8.2× · PEG n/a · 15% evidence Relative strength 12.9/20 · Lead over its industry 21.2% · Lead over S&P 500 46.6% · 1 year 328.9% · 100% evidence · 4 of 12 weeks ahead Exact sum: 23.6 + 8.6 + 11 + 12.9 = 56.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) MRNA · leader · Evidence leans up · 64% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue -27.6% · Profit n/a · Operating margin change 80.8 points · 62% evidence Capital efficiency 6.5/25 · ROCE -28.9% · Operating margin -557.9% · 76% evidence Valuation 11.2/20 · P/E -11.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 161.6% · Lead over S&P 500 205.6% · 1 year 882.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.4 + 6.5 + 11.2 + 20 = 55.1 · What this means: Relative strength against the index is 205.6%, and revenue and profit growth are weak. 10. [Krystal Biotech, Inc.](https://www.sectoralpha.in/us/stocks/krys) KRYS · quiet · Evidence leans up · 81% evidence 55.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 22.6% · Profit 65.1% · Operating margin change 8 points · 83% evidence Capital efficiency 16.1/25 · ROCE 14.4% · Operating margin 49% · 76% evidence Valuation 12.4/20 · P/E 45.4× · PEG 0.77 · 65% evidence Relative strength 4.1/20 · Lead over its industry -19% · Lead over S&P 500 0.1% · 1 year 51.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 22.4 + 16.1 + 12.4 + 4.1 = 55 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) JAZZ · quiet · Evidence leans up · 74% evidence 55.0 out of 100 Growth Capital Valuation Relative
12. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) RPRX · turning · Evidence leans up · 81% evidence 53.7 out of 100 Growth Capital Valuation Relative
13. [Regeneron Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/regn) REGN · leader · Evidence leans up · 81% evidence 52.8 out of 100 Growth Capital Valuation Relative
14. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) ALNY · basing · Evidence leans up · 64% evidence 51.6 out of 100 Growth Capital Valuation Relative
15. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) PTGX · losing its lead · Evidence leans down · 74% evidence 49.6 out of 100 Growth Capital Valuation Relative
16. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) VRTX · breaking out · Evidence leans down · 85% evidence 46.9 out of 100 Growth Capital Valuation Relative
17. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) TECH · turning · Evidence leans down · 74% evidence 44.4 out of 100 Growth Capital Valuation Relative
18. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) ROIV · turning · Too little evidence to rank firmly · 60% evidence 39.5 out of 100 Growth Capital Valuation Relative
19. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) SMMT · breaking out · Too little evidence to rank firmly · 53% evidence 39.2 out of 100 Growth Capital Valuation Relative
20. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) RVMD · quiet · Too little evidence to rank firmly · 53% evidence 38.7 out of 100 Growth Capital Valuation Relative
21. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) MDGL · quiet · Evidence leans down · 61% evidence 37.2 out of 100 Growth Capital Valuation Relative
22. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) INSM · basing · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
23. [BridgeBio Pharma, Inc.](https://www.sectoralpha.in/us/stocks/bbio) BBIO · quiet · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
24. BioNTech SE this page BNTX · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.4/35 · Revenue -8% · Profit n/a · Operating margin change -641.6 points · 62% evidence Capital efficiency 7.9/25 · ROCE -10.2% · Operating margin -806.6% · 76% evidence Valuation 11.3/20 · P/E -39.7× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -30.8% · Lead over S&P 500 -13.5% · 1 year -16.8% · 100% evidence · 2 of 12 weeks ahead Exact sum: 9.4 + 7.9 + 11.3 + 4.5 = 33.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 25. [BioMarin Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/bmrn) BMRN · quiet · Most evidence points down · 81% evidence 26.8 out of 100 Growth Capital Valuation Relative
26. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) ASND · turning · Too little evidence to rank firmly · 44% evidence 63.3 out of 100 Growth Capital Valuation Relative
27. Apogee Therapeutics, Inc. APGE · Too little evidence to rank firmly · 27% evidence 47.2 out of 100 Growth Capital Valuation Relative
28. Nuvalent, Inc. NUVL · Too little evidence to rank firmly · 20% evidence 41.2 out of 100 Growth Capital Valuation Relative
29. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) CRNX · Too little evidence to rank firmly · 35% evidence 38.0 out of 100 Growth Capital Valuation Relative
30. Vaxcyte, Inc. PCVX · breaking out · Too little evidence to rank firmly · 47% evidence 37.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Biotechnology](https://www.sectoralpha.in/us/sectors/biotechnology), all 30 compared on one page. ## Which companies are close to BioNTech SE in size? BioNTech SE is the 12th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Roivant Sciences, Incyte Corporation and Insmed Incorporated. Just below it: Alnylam Pharmaceuticals, Inc., Exelixis, Inc. and Ascendis Pharma A/S. ### Biotechnology companies close in size

1. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) $26.5 billion
2. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) $24.1 billion
3. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) $23.9 billion
4. BioNTech SE $21.3 billion
5. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) $21 billion
6. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) $16.8 billion
7. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) $16.6 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Reliance, Inc.](https://www.sectoralpha.in/us/stocks/rs) $22.5 billion · Steel
2. [Equifax Inc.](https://www.sectoralpha.in/us/stocks/efx) $22.5 billion · Consulting Services
3. BioNTech SE $22.5 billion
4. [Amcor plc](https://www.sectoralpha.in/us/stocks/amcr) $22.4 billion · Packaging & Containers
5. [International Flavors & Fragrances Inc.](https://www.sectoralpha.in/us/stocks/iff) $22.4 billion · Specialty Chemicals

## What else do people ask about BioNTech SE? ### What were BioNTech SE's latest quarterly results? BioNTech SE reported revenue of $106 M and a net loss of $821 M for the Jun 2026 quarter. Earnings per share were −$3.24. The operating margin was −806.6%, 641.6 percentage points lower than a year earlier (as of 5 November 2026). ### What is BioNTech SE's market cap? BioNTech SE's market capitalisation is $21.3 B at a stock price of $85.84. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is BioNTech SE performing? BioNTech SE's share price has been falling for 6 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 4 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will BioNTech SE's stock price go up? This page does not forecast BioNTech SE's stock price. What it shows instead: the stock price is $85.84, and it has been falling for 6 weeks. Its P/E of 243.9× is higher than 96% of its own last 3 years (as of 5 November 2026). ### Where is BioNTech SE in its business cycle? BioNTech SE's FY25 operating margin was −44.1%, against a 5-year range of −46.7% to 78.2%: the low end of its own range, which is often where recoveries start. The latest quarter was −806.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the BioNTech SE story? Biggest thing to watch: the P/E is higher than 96% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is BioNTech SE a stock worth studying right now? What the numbers show: BioNTech SE's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.